文献速递临床试验与 GCP

覆膜支架与裸金属支架治疗慢性动脉粥样硬化性胃肠道缺血(CoBaGI):随机对照试验研究方案

Covered stents versus Bare-metal stents in chronic atherosclerotic Gastrointestinal Ischemia (CoBaGI): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2019-08-20

CoBaGI试验是一项在荷兰肠缺血研究组六中心开展的随机对照、平行分组、患者与研究者盲法、优效性、多中心试验,计划纳入84例共识诊断为动脉粥样硬化性慢性肠系膜缺血的患者,1:1随机接受球囊扩张式裸金属支架(Palmaz Blue)或覆膜支架(Advanta V12)。主要终点为24个月时经CT血管造影评估的一期支架通畅率;次要终点包括6和12个月一期通畅率、二期通畅率、免于再狭窄、免于症状复发、免于再干预、生活质量及成本效果。

要点

  • CoBaGI试验在荷兰肠缺血研究组六中心开展,计划纳入84例动脉粥样硬化性慢性肠系膜缺血患者。
  • 患者1:1随机接受球囊扩张式裸金属支架(Palmaz Blue)或覆膜支架(Advanta V12)。
  • 主要终点为24个月时CT血管造影评估的一期支架通畅率。

核心结论

  • CoBaGI试验旨在评估覆膜支架与裸金属支架治疗动脉粥样硬化性肠系膜狭窄所致慢性肠系膜缺血患者的通畅率。
  • 该试验还旨在提供支架置入前后患者生活质量及成本效果的信息。
  • CoBaGI试验是首个在动脉粥样硬化性肠系膜动脉狭窄所致慢性肠系膜缺血中开展的随机对照试验。

研究设计与样本

  • CoBaGI试验为随机对照、平行分组、患者与研究者盲法、优效性、多中心试验,在荷兰肠缺血研究组(DMIS)六个中心开展。
  • 计划纳入84例共识诊断为动脉粥样硬化性慢性肠系膜缺血的患者,1:1随机接受球囊扩张式裸金属支架(Palmaz Blue,快速交换递送系统,Cordis Corporation,Bridgewater,NJ,USA)或球囊扩张式覆膜支架(Advanta V12 over-the-wire,Atrium Maquet Getinge Group,Hudson,NH,USA)。

关键数值与推荐

  • 主要终点为24个月时经CT血管造影评估的一期支架通畅率。
  • 次要终点包括6和12个月一期支架通畅率、二期通畅率、免于再狭窄、免于症状复发、免于再干预、按EQ-5D-5L和SF-36评估的生活质量及6、12和24个月的成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic mesenteric ischemia (CMI) is the result of insufficient blood supply to the gastrointestinal tract and is caused by atherosclerotic stenosis of one or more mesenteric arteries in > 90% of cases. Revascularization therapy is indicated in patients with a diagnosis of atherosclerotic CMI to relieve symptoms and to prevent acute-on-chronic mesenteric ischemia, which is associated with high morbidity and mortality. Endovascular therapy has rapidly evolved and has replaced surgery as the first choice of treatment in CMI. Bare-metal stents (BMS) are standard care currently, although retrospective studies suggested significantly higher patency rates for covered stents (CS). The Covered stents versus Bare-metal stents in chronic atherosclerotic Gastrointestinal Ischemia (CoBaGI) trial is designed to prospectively assess the patency of CS versus BMS in patients with atherosclerotic CMI. METHODS/DESIGN: The CoBaGI trial is a randomized controlled, parallel-group, patient- and investigator-blinded, superiority, multicenter trial conducted in six centers of the Dutch Mesenteric Ischemia Study group (DMIS). Eighty-four patients with a consensus diagnosis of atherosclerotic CMI are 1:1 randomized to either a balloon-expandable BMS (Palmaz Blue with rapid-exchange delivery system, Cordis Corporation, Bridgewater, NJ, USA) or a balloon-expandable CS (Advanta V12 over-the-wire, Atrium Maquet Getinge Group, Hudson, NH, USA). The primary endpoint is the primary stent-patency rate at 24 months assessed with CT angiography. Secondary endpoints are primary stent patency at 6 and 12 months and secondary patency rates, freedom from restenosis, freedom from symptom recurrence, freedom from re-intervention, quality of life according the EQ-5D-5 L and SF-36 and cost-effectiveness at 6, 12 and 24 months. DISCUSSION: The CoBaGI trial is designed to assess the patency rates of CS versus BMS in patients treated for CMI caused by atherosclerotic mesenteric stenosis. Furthermore, the CoBaGI trial should provide insights in the quality of life of these patients before and after stenting and its cost-effectiveness. The CoBaGI trial is the first randomized controlled trial performed in CMI caused by atherosclerotic mesenteric artery stenosis. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT02428582 . Registered on 29 April 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. van Dijk LJD, Harki J, van Noord D, et al. Covered stents versus Bare-metal stents in chronic atherosclerotic Gastrointestinal Ischemia (CoBaGI): study protocol for a randomized controlled trial. Trials. 2019. PMID: 31429792. doi:10.1186/s13063-019-3609-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。